Newly marketed targeted antitumor drugs have emerged rapidly, and as a result of their higher selectivity than conventional chemotherapy, they tend to be more effective in the right patient population. However, there are limitations to conventional chemotherapy, including the possibility of developing resistance and unwanted side effects, as well as the variability in patient responses. For these specific reasons, the establishment of preclinical and clinical detection methods of targeted antitumor drugs (including liquid chromatographic, mass detection with triple quadrupole, and high-resolution mass spectrometry) in rats, mice, rabbit, monkey, and humans and their metabolism situations could provide therapeutic drug monitoring (TDM) and clinical drug-drug interactions (DDIs) of targeted drugs with a foundation for patient management. These bioanalytical methods and metabolism studies of new targeted antitumor drugs are essential and play an important role in the efficacy and safety management of this class of drugs in the future.
Currently, there are many new targeted antitumor drugs under clinical development, some are even already approved by the FDA. As a consequence, there is an increasing demand for qualitative and quantitative measurements using bioanalytical methods. A major focus of this Research Topic is on chromatographic analytical methods that allow quantification of newly marketed targeted antitumor drugs in plasma, cerebrospinal fluid, urine, tissues, and liver microsomes using various biometrics. Among other areas of interest, we will also consider the pharmacokinetics and drug-drug interactions of new targeted antitumor drugs, as well as their metabolites and biotransformation pathways.
We encourage authors to submit Original Research, Systematic Review, Review, Opinion, and Perspective articles, in the following subtopics, but not limited to:
• the bioanalysis of new targeted antitumor drugs, including developments in analytical methodology, instrumentation, computation, and interpretation
• novel applications focusing on new targeted antitumor drugs, including pharmacokinetics, drug-drug interactions, therapeutic monitoring, and metabolic profiling
•antitumor drug-related aspects of potential toxicity
• drug, liver drug enzyme CYP, and transporter polymorphism factors on the metabolism of new targeted antitumor drugs
Newly marketed targeted antitumor drugs have emerged rapidly, and as a result of their higher selectivity than conventional chemotherapy, they tend to be more effective in the right patient population. However, there are limitations to conventional chemotherapy, including the possibility of developing resistance and unwanted side effects, as well as the variability in patient responses. For these specific reasons, the establishment of preclinical and clinical detection methods of targeted antitumor drugs (including liquid chromatographic, mass detection with triple quadrupole, and high-resolution mass spectrometry) in rats, mice, rabbit, monkey, and humans and their metabolism situations could provide therapeutic drug monitoring (TDM) and clinical drug-drug interactions (DDIs) of targeted drugs with a foundation for patient management. These bioanalytical methods and metabolism studies of new targeted antitumor drugs are essential and play an important role in the efficacy and safety management of this class of drugs in the future.
Currently, there are many new targeted antitumor drugs under clinical development, some are even already approved by the FDA. As a consequence, there is an increasing demand for qualitative and quantitative measurements using bioanalytical methods. A major focus of this Research Topic is on chromatographic analytical methods that allow quantification of newly marketed targeted antitumor drugs in plasma, cerebrospinal fluid, urine, tissues, and liver microsomes using various biometrics. Among other areas of interest, we will also consider the pharmacokinetics and drug-drug interactions of new targeted antitumor drugs, as well as their metabolites and biotransformation pathways.
We encourage authors to submit Original Research, Systematic Review, Review, Opinion, and Perspective articles, in the following subtopics, but not limited to:
• the bioanalysis of new targeted antitumor drugs, including developments in analytical methodology, instrumentation, computation, and interpretation
• novel applications focusing on new targeted antitumor drugs, including pharmacokinetics, drug-drug interactions, therapeutic monitoring, and metabolic profiling
•antitumor drug-related aspects of potential toxicity
• drug, liver drug enzyme CYP, and transporter polymorphism factors on the metabolism of new targeted antitumor drugs